Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.58 |
| ▸ | CNR2 | P34972 | 1/20 | 0.58 |
| ▸ | CASR | P41180 | 3/20 | 0.54 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.52 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.46 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5453708 | 0.92 | POLB (0.55) | CNR1CNR2CASRMEN1KMT2A | |
| SCHEMBL5451806 | 0.88 | CNR1 (0.56) | CNR1CNR2CASRMTNR1AMTNR1B | |
| SCHEMBL5463285 | 0.84 | MTNR1A (0.51) | CNR1CNR2CASRMTNR1AMTNR1B | |
| SCHEMBL5451818 | 0.82 | MTNR1A (0.52) | CNR1CNR2CASRMTNR1AMTNR1B | |
| SCHEMBL5449619 | 0.82 | CNR1 (0.47) | CNR1CNR2CASRMTNR1AMTNR1B | |
| SCHEMBL5446508 | 0.82 | MTNR1B (0.53) | CNR1CNR2CASRMTNR1AMTNR1B | |
| SCHEMBL5454530 | 0.80 | DRD2 (0.58) | CNR1MEN1KMT2APOLBPRMT5 | |
| SCHEMBL5451842 | 0.78 | MTNR1A (0.44) | CNR1CNR2CASRMTNR1AMTNR1B | |
| SCHEMBL5451891 | 0.78 | MTNR1A (0.48) | CNR1CNR2CASRMTNR1AMTNR1B | |
| SCHEMBL5452635 | 0.76 | CNR1 (0.46) | CNR1CNR2CASRMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043024-A1 | Azacyclic compounds as inhibitors of sensory neurone specific channels | IONIX PHARMACEUTICALS LIMITED (GB) | 2007-02-22 | — | — | US | disclosed |
| EP-1660454-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC CHANNELS | Vernalis (R&D) Limited (GB) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005005392-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC CHANNELS | IONIX PHARMACEUTICALS LIMITED (GB) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043024-A1 | Azacyclic compounds as inhibitors of sensory neurone specific channels | SCN1B, SCN1A, SCN10A | CNR1 336/4885CNR2 463/4885CASR 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.